What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 2, Pre-Registered Trial).

What question did this study set out to answer?

To evaluate the feasibility of loncastuximab tesirine as a consolidation strategy for patients with large B-cell lymphoma after CAR T-cell therapy.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Phase II trial demonstrates safety and efficacy of antibody-drug conjugate in patients with partial response, indicating potential for further study.

To evaluate the feasibility of loncastuximab tesirine as a consolidation strategy for patients with large B-cell lymphoma after CAR T-cell therapy.
Single arm phase II trial involving patients with relapsed or refractory large B-cell lymphoma
Administered loncastuximab tesirine intravenously over 6 cycles
Evaluated toxicity using CTCAE v5 and response using Lugano 2014 criteria
Conducted an interim futility analysis after 10 patients completed treatment
40% of patients converted to complete response after treatment
Common grade 3-4 adverse events included thrombocytopenia and neutropenia, affecting 60% of patients
50% of patients discontinued treatment before completion, primarily due to disease progression or unacceptable toxicities

Zaki et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase II trial demonstrates safety and efficacy of antibody-drug conjugate in patients with partial response, indicating potential for further study.